Updates are available Correction dated 2026-03-02
Click to view Correction: https://doi.org/10.1038/s41409-026-02809-0
-
Authors
Canelo-Vilaseca, Marta https://orcid.org/0000-0003-4479-4925
Sabbah, Mohamad
Cristinelli, Caterina
Bommier, Côme
Sesques, Pierre
Roussel, Mikael
Bories, Pierre
Allain, Vincent
Ouedrani, Amani
De Bernardis, Ilenia
Vely, Agathe
Stephan, Pierre https://orcid.org/0000-0001-5999-284X
Vercellino, Laetitia
Venet, Fabienne
Pescarmona, Rémi
Houot, Roch
Vergez, François
de Jorna, Romain
Madelaine, Isabelle
Parquet, Nathalie
Brignier, Anne C.
Larghero, Jérôme
Mebarki, Miryam
Di Blasi, Roberta
Caillat-Zucman, Sophie https://orcid.org/0000-0002-4535-3550
Thieblemont, Catherine https://orcid.org/0000-0002-9941-2448
- License Information
-
More Information
Article History
Received: 20 June 2025
Revised: 22 July 2025
Accepted: 7 November 2025
First Online: 8 January 2026
Change Date: 26 February 2026
Change Type: Update
Change Details: The original online version of this article was revised: In this article the author name have been misspelled: The correct full names are : Côme (name) BOMMIER (surname) ; Roberta (name) DI BLASI (surname).
Change Date: 2 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-026-02809-0
Competing interests
: MC-V declares no COI. MS declares no COI. CC has received honoraria from AbbVie. PSesques has received honoraria from AbbVie, BMS, Chugai, Janssen, Kite/Gilead, Novartis and Roche. MR declares no COI. PB has received honoraria from Abbvie, Beigene, BMS, Novartis, Kyte-Gilead, Servier. VA declares no COI. AO declares no COI. IDB declares no COI. AV declares no COI. CB declares advisory fees from JNJ, BMS, BeiGene, Abbvie, Cureety (consulting); JNJ, BeiGene (honoraria); from Institut Servier (research funding). PStephan. LV has received honoraria from Kite/Gilead, acted as consultant for Pixilib and Genmab; received hospitality from MSD France, Siemens Healthcare and Sanofi Aventis. FV declares no COI. RP declares no COI. RH has received honoraria from Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, Incyte, Janssen, MSD, Takeda, Amgen, Abbvie, and Roche; and is a member on an entity’s Board of Directors or advisory committees of Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, Tessa Therapeutics, Abbvie and Roche. RDJ declares no COI. IS declares no COI. NP declares no COI. ACB declares no COI. JL declares no COI. MM: declares no COI. RDB has received honoraria from Kite/Gilead, Novartis, BMS, Amgen, Abbvie and Roche. SC-Z: declares no COI. CT: reports membership on an entity’s Board of Directors or advisory committees of Kite, Amgen, AbbVie, Novartis, Roche, Gilead, Takeda, BMS/Celgene, Incyte, and Cellectis; consultancy for Kite, Amgen, AbbVie, Novartis, Gilead, Cellectis, Roche, and BMS/Celgene; honoraria from Takeda, Incyte, Bayer, Kite, Gilead, Novartis, BMS, Abbvie, F. Hoffmann-La Roche Ltd, Amgen, Cellectis, and Janssen; research funding from Hospira and BMS/Celgene; and support for attending meetings and/or travel from Kite Pharma / Gilead, Amgen, AbbVie, Novartis, Gilead, Cellectis, Roche, BMS/Celgene, and Janssen.
